Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice.
Adult
Aged
Animals
Antigens, CD20
/ immunology
Antineoplastic Agents, Immunological
/ administration & dosage
B-Lymphocytes
/ immunology
Bone Density
/ drug effects
Bone Resorption
/ therapy
Cross-Sectional Studies
Female
Humans
Immunotherapy
/ methods
Lymphocyte Depletion
Lymphoma, Follicular
/ therapy
Male
Mice
Mice, Inbred C57BL
Middle Aged
Positron Emission Tomography Computed Tomography
Retrospective Studies
Rituximab
/ administration & dosage
Treatment Outcome
B cell depletion
CD115
RANKL (receptor activator for nuclear factor k B ligand)
anti-CD20 antibodies
bone density
follicular lymphoma
rituximab
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
05
2020
accepted:
21
08
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
4
5
2021
Statut:
epublish
Résumé
Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet been described. Here, we used cross-sectional X-ray imaging (CT/PET-CT) to serially assess bone density in patients with follicular lymphoma receiving rituximab maintenance therapy. Remarkably, this treatment prevented the decline in bone mass observed in the control group of patients who did not receive active maintenance therapy. In accordance with these data, anti-CD20-mediated B cell depletion in normal C57BL/6J female mice led to a significant increase in bone mass, as reflected by a 7.7% increase in bone mineral density (whole femur), and a ~5% increase in cortical as well as trabecular tissue mineral density. Administration of anti-CD20 antibodies resulted in a significant decrease in osteoclastogenic signals, including RANKL, which correlated with a reduction in osteoclastogenic potential of bone marrow cells derived from B-cell-depleted animals. Taken together, our data suggest that in addition to its anti-tumor activity, anti-CD20 treatment has a favorable effect on bone mass. Our murine studies indicate that B cell depletion has a direct effect on bone remodeling.
Identifiants
pubmed: 33193330
doi: 10.3389/fimmu.2020.561294
pmc: PMC7604358
doi:
Substances chimiques
Antigens, CD20
0
Antineoplastic Agents, Immunological
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
561294Informations de copyright
Copyright © 2020 Kolomansky, Kaye, Ben-Califa, Gorodov, Awida, Sadovnic, Ibrahim, Liron, Hiram-Bab, Oster, Sarid, Perry, Gabet, Mittelman and Neumann.
Références
Lupus. 2013 Oct;22(11):1128-34
pubmed: 23989736
Immunity. 2017 Jul 18;47(1):171-182.e4
pubmed: 28723549
J Bone Miner Res. 2000 Aug;15(8):1477-88
pubmed: 10934646
Biochem Biophys Res Commun. 1993 Jul 15;194(1):391-8
pubmed: 8333855
Nat Immunol. 2001 Jan;2(1):83-8
pubmed: 11135583
J Biol Chem. 2012 Aug 24;287(35):29851-60
pubmed: 22782898
Front Oncol. 2018 Jun 04;8:163
pubmed: 29915719
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):125-30
pubmed: 12490655
J Bone Miner Res. 2004 Jul;19(7):1137-43
pubmed: 15176997
J Biol Chem. 2017 Jun 16;292(24):10169-10179
pubmed: 28438834
Blood. 2007 May 1;109(9):3839-48
pubmed: 17202317
Rheumatol Int. 2011 Feb;31(2):269-72
pubmed: 20661741
Blood. 2007 May 1;109(9):3706-12
pubmed: 17227831
FASEB J. 2015 May;29(5):1890-900
pubmed: 25630969
PLoS One. 2009;4(5):e5438
pubmed: 19412553
Arthritis Rheumatol. 2016 Apr;68(4):805-16
pubmed: 26554541
J Clin Invest. 1994 Sep;94(3):1090-7
pubmed: 8083350
J Immunol. 2001 Feb 1;166(3):1482-91
pubmed: 11160187
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1566-71
pubmed: 10677500
Am J Gastroenterol. 2014 Mar;109(3):401-8
pubmed: 24445572
J Bone Miner Res. 2001 Dec;16(12):2215-21
pubmed: 11760834
J Autoimmun. 2017 Jan;76:53-62
pubmed: 27640100
Bone. 2017 Aug;101:62-69
pubmed: 28442297
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
Bone. 2010 Sep;47(3):472-9
pubmed: 20601290
J Immunol. 2001 Sep 1;167(5):2625-31
pubmed: 11509604
J Bone Miner Res. 2016 Jul;31(7):1320-33
pubmed: 26825871
PLoS One. 2018 Aug 6;13(8):e0201527
pubmed: 30080871
Calcif Tissue Int. 2018 May;102(5):607-618
pubmed: 29470611
J Biol Chem. 2016 Nov 25;291(48):24838-24850
pubmed: 27733688
Am J Hematol. 2012 Oct;87(10):988-95
pubmed: 23001911
Eur J Immunol. 2001 Jul;31(7):2179-88
pubmed: 11449372
Calcif Tissue Int. 1996 Jan;58(1):24-9
pubmed: 8825235
Blood. 2010 Nov 11;116(19):3964-71
pubmed: 20716776
Leuk Lymphoma. 2017 May;58(5):1105-1113
pubmed: 27736260
Immunol Today. 1989 May;10(5):170-3
pubmed: 2663018
Blood. 2011 Mar 17;117(11):3104-12
pubmed: 21228330
Nat Rev Endocrinol. 2013 Dec;9(12):699-712
pubmed: 24042328
Biomed Res Int. 2015;2015:421746
pubmed: 26247020
Theranostics. 2020 Jul 9;10(19):8744-8756
pubmed: 32754275
J Bone Miner Res. 2006 Sep;21(9):1339-49
pubmed: 16939392
Front Immunol. 2016 Mar 22;7:77
pubmed: 27047488
Aging Cell. 2019 Aug;18(4):e12959
pubmed: 31056853
Exp Mol Med. 2003 Oct 31;35(5):385-92
pubmed: 14646592
Genes Dev. 1999 Sep 15;13(18):2412-24
pubmed: 10500098
Ann Rheum Dis. 2007 Jun;66(6):818-20
pubmed: 17148544